A5019315994- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Glycosylation and Glycoproteins Research
- Ubiquitin and proteasome pathways
- Nanoplatforms for cancer theranostics
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Glioma Diagnosis and Treatment
- Galectins and Cancer Biology
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Protein Tyrosine Phosphatases
- RNA Research and Splicing
Centro de Biología Molecular Severo Ochoa
2022-2025
Universidad Autónoma de Madrid
2022-2025
Consejo Superior de Investigaciones Científicas
2022-2025
University Medical Center Utrecht
2017
The small GTPase R-RAS2 regulates homeostatic proliferation and survival of T B lymphocytes and, when present in high amounts, drives the development cell chronic lymphocytic leukemia. In normal leukemic lymphocytes, constitutively binds to antigen receptors through their immunoreceptor tyrosine-based activation motifs (ITAMs) promotes tonic phosphatidylinositol 3-kinase (PI3K) signaling pathway. Here, we examined molecular mechanisms underlying this direct interaction its consequences for...
Chronic lymphocytic leukemia (CLL) is the most frequent, and still incurable, form of in Western World. It widely accepted that cancer results from an evolutionary process shaped by acquisition driver mutations which confer selective growth advantage to cells harbor them. Clear examples are missense classic RAS genes (KRAS, HRAS NRAS) underlie development approximately 13% human cancers. Although autonomous B cell antigen receptor (BCR) signaling involved many tumor suppressor oncogenes have...
Abstract Background Breast cancer (BC) is the most common in women, with triple negative BC (TNBC) accounting for 20% of cases. While early detection and targeted therapies have improved overall life expectancy, TNBC remains resistant to current treatments. Although parity reduces lifetime risk developing BC, pregnancy increases years after childbirth. numerous gene mutations been associated no single alteration has identified as a universal driver. RRAS2 RAS-related GTPase rarely found...
Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by progressive accumulation of rare population CD5+ B-lymphocytes in peripheral blood, bone marrow, and lymphoid tissues. CLL exhibits remarkable clinical heterogeneity, with some patients presenting indolent disease others progressing rapidly to aggressive CLL. The significant heterogeneity underscores the importance identifying novel prognostic markers. Recently, RAS-related gene RRAS2 has emerged as both driver...
B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of in Western world. Mutations different genes, such as TP53 and ATM, deletions specific chromosomal regions, including 11q or 17p, have been associated with a worse prognosis for disease. Recent research from our group has demonstrated that, contrary to usual cancer development process through missense mutations, B-CLL driven by overexpression small GTPase RRAS2 its wild-type form, without activating mutations. While some...
Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by progressive accumulation of rare population CD5+ B lymphocytes in peripheral blood, bone marrow and lymphoid tissues. CLL exhibits remarkable clinical heterogeneity, with some patients presenting indolent disease others progressing rapidly to aggressive CLL. The significant heterogeneity underscores the importance identifying novel prognostic markers. Recently, RAS-related gene RRAS2 has emerged as both driver...
B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of in Western world. Mutation different genes, such as